New Ampyra(R) (dalfampridine) study data reported at ECTRIMS

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

New Ampyra(R) (dalfampridine) study data reported at ECTRIMS

Postby MSUK » Fri Oct 15, 2010 10:18 am

Image

Responders to Ampyra Showed Clinically Significant and Meaningful Improvement in Walking Ability Based on Recent Consensus Expert Group Criteria.

Acorda Therapeutics, Inc. today announced that a new analysis of AMPYRA(R) (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Ampyra is an oral medication approved by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2184
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service